Work

Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!

Year: 2012

Type: article

Abstract: Patients with non-small cell lung carcinoma containing epidermal growth factor receptor (EGFR)-activating mutations benefit from EGFR-antagonist therapy. EGFR-antagonist sensitivity is also correlated with epithelial-mesenchymal transition, which Walter and colleagues show to be marked by DNA-methylation changes. If validated, these markers could help identify patients with wild-type EGFR who will benefit from EGFR therapy.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-12-0157

Authors: Hariharan Easwaran, Stephen B. Baylin

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute